Radiolabelling morpholinos with re tricarbonyl provides improved in vitro and in vivo stability to re-oxidation

Nuclear Medicine Communications

Volumn 25, Issue 7, 2004, Pages 731-736

  He, Jiang ^a   Liu, Changbin ^a   Vanderheyden, Jean Luc ^a   Liu, Guozheng ^a   Dou, Shuping ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Morpholinos; Oxidation; Radiopharmaceuticals; Re tricarbonyl

Indexed keywords

OLIGONUCLEOTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM; AMINE; BUFFER; CHELATING AGENT; MERCAPTOACETYLTRIGLYCINE; MERCAPTOACETYLTRIGLYCINE PHOSPHODIAMIDATE MORPHOLINORHENIUM RE 188; MORPHOLINE DERIVATIVE; N HYDROXYSUCCINIMIDYLHYDRAZINONICOTINAMIDE; N HYDROXYSUCCINIMIDYLMERCAPTOACETYLTRIGLYCINE; PHOSPHATE; POLYMER; REDUCING AGENT; RHENIUM 188; SUCCINIC ACID DERIVATIVE; TECHNETIUM 99M; TRICARBONYL N HYDROXYSUCCINIMIDYLPHOSPHODIAMIDATE MORPHOLINORHENIUM RE 188; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG STABILITY; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; METHODOLOGY; MOUSE; OXIDATION REDUCTION REACTION; SYNTHESIS; TISSUE DISTRIBUTION; ANIMAL TISSUE; APPARATUS; ASSAY; BIOAVAILABILITY; CHROMATOGRAPHY; CONJUGATION; CONTROLLED STUDY; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH TEMPERATURE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; MEASUREMENT; NONHUMAN; OXIDATION; STOMACH; THYROID GLAND; TIME;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; OLIGONUCLEOTIDES; ORGAN SPECIFICITY; OXIDATION-REDUCTION; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION;

EID: 2942675512     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000130237.91573.34     Document Type: Article

References (19)

1. 99mTc-labeled morpholinos for radiopharmaceutical applications. Eur J Nucl Med 2001; 28:1682-1689.
2. 99mTc labeled morpholinos, a DNA analog. J Nucl Med 2002; 43:384-391.
3. 99mTc. Nucl Med Biol 2003; 30:207-214.
4. Deutsch E, Libson K, Vanderheyden J-L. The inorganic chemistry of technetium and rhenium as relevant to nuclear medicine. In: Nicolini M, Bandoli G, Mazzi U (editors). Technetium and Rhenium in Chemistry and Nuclear Medicine. New York: Raven Press; 1990, pp. 13-22.
5. +. Bioconjugate Chem 2002; 13:750-756.
6. Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med 2002; 29:1529-1542.
7. 3 for technetium-99m labeling of DNA. Nucl Med Biol 1997; 24:425-432.
8. Wang Y, Chang F, Zhang Y, Liu N, Liu G, Gupta S, et al. Pretargeting with amplification using polymeric peptide nucleic acid (PNA). Bioconjugate Chem 2001; 12:807-816.
9. 3 and SHNH - an in vitro and animal in vivo comparison. Nucl Med Biol 1996; 23:917-922.
10. 3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med 2001; 27:1700-1707.
11. 99mTc. Nucl Med Commun 2001; 22:203-215.
12. 99mTc(I)-tricarbonyl complexes: A hint for the further functionalization of biomolecules. Bioconjugate Chem 2000; 11:345-351.
13. +-core. Nucl Med Biol 1999; 26:711-716.
14. 3 moieties to biological active molecules. Bioconjugate Chem 2000; 11:414-424.
15. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Pretargeting using peptide nucleic acid (PNA). Cancer 1997; 80:2699-2705.
16. 99mTc morpholino pretargeting in mice. Nucl Med Commun 2003; 24:697-700.
17. Rhodes BA, Lambert CR, Marek MJ, Knapp FF, Harvey EB. Re-188 labelled antibodies. Appl Radiat Isot 1996; 47:7-14.
18. 188Re. Q J Nucl Med 1996; 40:151-160.
19. 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999; 40:1913-1917.